Lotus Eye Hospital And Institute Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.65x)
- Working capital cycle has improved - days down from 58 to 31
- Company generates healthy free cash flow
CONS
- Recent results are weak - TTM profit is down 86.1% versus prior year
- A large part of profit comes from other income (94.1% of PBT)
- Company has a low return on equity of 4.5% over last 3 years
- Company has a low return on capital employed of 6.9%
- Company has delivered a poor profit growth of -7.0% over past five years
- Operating margins have contracted to 7.2% from 17.5%
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP | 8850.00 | 60.90 | 127249.42 | 0.23 | 610.40 | 38.41 | 7043.50 | 20.56 | 21.73 | 15.70 |
| MAXHEALTH | 1037.20 | 69.29 | 100951.74 | 0.19 | 322.96 | 4.87 | 2366.17 | 16.70 | 14.97 | 25.29 |
| MANIPALHOS | 716.15 | 105.57 | 94200.74 | 0.00 | 2434.30 | — | 30906.30 | — | 13.93 | 23.83 |
| FORTIS | 887.30 | 63.93 | 66987.44 | 0.11 | 272.80 | 2.26 | 2545.03 | 17.46 | 14.07 | 21.28 |
| ASTERDM | 762.95 | 208.69 | 66504.25 | 0.39 | 29.28 | -68.70 | 1310.68 | 21.60 | 11.26 | 19.53 |
| MEDANTA | 1447.55 | 69.98 | 38920.53 | 0.03 | 157.25 | -1.09 | 1304.05 | 26.50 | 19.38 | 21.99 |
| NH | 1867.35 | 46.76 | 38161.31 | 0.24 | 207.27 | 5.37 | 2683.63 | 78.05 | 16.20 | 17.43 |
| KIMS | 768.85 | 158.06 | 32292.20 | 0.00 | 37.40 | -56.00 | 1179.50 | 35.33 | 11.51 | 19.03 |
| LALPATHLAB | 1909.40 | 59.14 | 32049.05 | 1.07 | 1705.00 | 1172.39 | 7977.00 | 1090.95 | 29.56 | 31.03 |
| AGARWALEYE | 507.00 | 108.33 | 16073.23 | 0.00 | 55.02 | 44.56 | 614.02 | 25.97 | 16.14 | 27.75 |
| VIJAYA | 1502.30 | 82.53 | 15473.35 | 0.13 | 53.10 | 37.61 | 230.98 | 22.83 | 30.28 | 42.66 |
| LOTUSEYE | 113.25 | 1570.12 | 235.52 | 0.00 | 0.61 | 11.64 | 17.06 | 26.16 | 3.10 | 17.27 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 | 13 | 12 | 11 | 13 | 13 | 12 | 12 | 14 | 13 | 14 | 14 | 17 | |
| 10 | 11 | 10 | 10 | 11 | 12 | 11 | 12 | 12 | 12 | 13 | 13 | 16 | |
| Operating Profit | 2 | 2 | 2 | 1 | 2 | 1 | 1 | -0 | 1 | 1 | 1 | 0 | 1 |
| OPM % | 18.93% | 14.22% | 13.13% | 6.89% | 12.88% | 8.83% | 6.45% | -1.48% | 10.95% | 5.90% | 4.87% | 3.53% | 4.71% |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | -1 | 1 | 1 | 1 | 1 | 2 |
| Profit before Tax | 2 | 1 | 1 | 0 | 1 | 0 | -0 | 1 | 1 | 0 | -0 | -0 | 1 |
| Tax % | 27.98% | 28.81% | 26.67% | -200.00% | 26.74% | 9.09% | 45.24% | 70.24% | 26.03% | -57.14% | 28.95% | 33.33% | 39.17% |
| Net Profit | 1 | 1 | 1 | 0 | 1 | 0 | -0 | 0 | 1 | 0 | -0 | -0 | 1 |
| 0.67 | 0.41 | 0.32 | 0.01 | 0.30 | 0.05 | -0.11 | 0.12 | 0.26 | 0.06 | -0.13 | -0.15 | 0.30 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 | 34 | 38 | 38 | 41 | 32 | 39 | 47 | 48 | 50 | 57 | |
| 28 | 31 | 34 | 35 | 37 | 29 | 33 | 39 | 42 | 46 | 55 | |
| Operating Profit | 3 | 3 | 4 | 3 | 4 | 4 | 6 | 8 | 7 | 4 | 3 |
| OPM % | 10.21% | 9.80% | 11.44% | 8.39% | 9.82% | 11.23% | 15.25% | 16.35% | 13.76% | 7.18% | 4.74% |
| 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 4 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 4 | 3 | 5 |
| Profit before Tax | -0 | 0 | 2 | 1 | 1 | 2 | 4 | 6 | 4 | 1 | 0 |
| Tax % | 591.71% | -6.14% | -2.60% | -12.77% | 26.86% | 21.29% | 27.09% | 27.86% | 27.39% | 46.53% | 38.91% |
| Net Profit | 0 | 0 | 2 | 1 | 1 | 2 | 3 | 4 | 3 | 1 | 0 |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.75 | 1.44 | 1.96 | 1.40 | 0.36 | — |
| Dividend Payout % | 0.00% | 234.19% | 59.53% | 0.00% | 0.00% | 66.31% | 34.84% | 25.50% | 35.68% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 5%
- 5 Years:
- 4%
- 3 Years:
- 8%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- -7%
- 3 Years:
- -37%
STOCK PRICE CAGR
- 10 Years:
- 22%
- 5 Years:
- 20%
- 3 Years:
- 9%
- 1 Year:
- -6%
RETURN ON EQUITY
- 10 Years:
- 3%
- 5 Years:
- 4%
- 3 Years:
- 4%
- Last Year:
- 1%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| 29 | 29 | 30 | 29 | 30 | 32 | 34 | 37 | 39 | 39 | |
| 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 3 | |
| Trade Payables | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 3 | 3 | 3 |
| 2 | 2 | 3 | 2 | 3 | 3 | 2 | 2 | 2 | 3 | |
| Total Liabilities | 55 | 55 | 57 | 56 | 57 | 58 | 61 | 63 | 66 | 69 |
| 44 | 41 | 43 | 44 | 43 | 41 | 44 | 44 | 49 | 54 | |
| Capital Work in Progress | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| Cash & Bank | 2 | 3 | 4 | 3 | 7 | 10 | 9 | 8 | 7 | 4 |
| 5 | 7 | 8 | 6 | 5 | 6 | 6 | 7 | 6 | 6 | |
| Total Assets | 55 | 55 | 57 | 56 | 57 | 58 | 61 | 63 | 66 | 69 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 3 | 6 | 4 | 5 | 3 | 5 | 6 | 6 | 3 | |
| Cash from Investing | -1 | -1 | -4 | -4 | -1 | 0 | -4 | -2 | -4 | -4 |
| Cash from Financing | -1 | -0 | -2 | -1 | 0 | -0 | -2 | -2 | -3 | -2 |
| 2 | 2 | 0 | -1 | 4 | 3 | -1 | 0 | -1 | -3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-01 - LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange about Copy of Newspaper Publication regarding 29th Annual General Meeting and Annual Report for the financial year 2025-26.
2026-09-01 - LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange about 29th Annual General Meeting scheduled to be held on September 23, 2026.
2026-08-27 - LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange regarding a press release dated August 27, 2026, titled "Launch of 'Lotus Optique', a new optical store.".
2026-08-11 - LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange about Copy of Newspaper Advertisements published for Standalone Unaudited Financial Results for the quarter ended June 30, 2026
2026-08-10 - LOTUSEYE: Lotus Eye Hospital and Institute Limited has submitted to the Exchange, the Standalone Unaudited Financial Results for the period ended June 30, 2026.
2026-07-06 - LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
2026-06-25 - Lotus Eye Hospital and Institute Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
2026-06-19 - Lotus Eye Hospital and Institute Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
2026-06-05 - LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange regarding the financial results for the period ended March 31, 2026 in machine readable format.
News
Recent coverage and analyst commentary for LOTUSEYE
Loading news…
AI Stock Analyst
Lotus Eye Hospital And Institute Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account